Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of 3-V Bioscience-2640, a FASN Inhibitor, to Reduce de Novo Lipogenesis in Subjects With Characteristics of the Metabolic Syndrome

NCT02948569 is registered in ClinicalTrials.gov with University of Missouri-Columbia as lead sponsor.

NCT NCT02948569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02948569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of 3-V Bioscience-2640, a FASN Inhibitor, to Reduce de Novo Lipogenesis in Subjects With Characteristics of the Metabolic Syndrome
Lead sponsor
University of Missouri-Columbia
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2017
Completion date
January 30, 2019
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome